Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Privately held-Covis Pharma, the maker of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth, said…
Reported Late Tuesday March 7, FDA Accepts Mesoblast’s Resubmission Of The Biologic License Application For Remestemcel-L In Children With Steroid-Refractory Acute Graft Versus Host Disease As A Complete Response And Sets Goal Date Of August 2, 2023
Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration's (FDA) Office of Therapeutic
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
FDA’s Regulatory Delay is The Reason For Novavax, Lucira Health’s Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb
‘Qualigen Peer-Reviewed Journal Article Out Titled “The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100p Gene Expression In Cells And In An In Vivo Model Of Pancreatic Cancer”‘
https://www.mdpi.com/1420-3049/28/6/2452
Abstract
The naphthalene diimide compound QN-302, designed to bind to G-quadruplex DNA sequences within the promoter regions of cancer-related genes, has high anti-proliferative
Caris Life Sciences Announced A Strategic Research Partnership With Incyte To Augment Precision Medicine Approaches For Incyte’s Oncology Pipeline; Deal Terms Not Disclosed
Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs.
For drug candidates developed under the
Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
More than 300,000 people in the